Sibylla Biotech announced a drug discovery collaboration with Ono Pharmaceutical Co., Ltd. that will access Sibylla?s Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology to identify and develop candidates for multiple therapeutic targets in the field of Central Nervous System (CNS) disorders. Under the terms of the collaboration, Sibylla is entitled to a total deal value in the three-digit millions of U.S. dollars, including upfront payment, research, development and sales milestones, and royalties on sales. Sibylla Biotech utilizes its PPI-FIT technology to design Folding Interfering Degraders (FIDs).

FIDs are small molecules that induce the degradation of a target protein by interfering with its folding pathway. The technology targets specific proteins, particularly those considered ?undruggable? due to the absence of suitable pockets in their native state.

Ono Pharmaceutical plans to harness this technology to address some of the most challenging aspects of CNS drug development by targeting proteins involved in complex neurological pathways.